Inovio Pharmaceuticals (INO)
(Real Time Quote from BATS)
$4.18 USD
+0.12 (2.96%)
Updated Nov 22, 2024 11:48 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
INO 4.18 +0.12(2.96%)
Will INO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for INO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INO
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates
INO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?
Other News for INO
Inovio price target lowered to $15 from $33 at Oppenheimer
Inovio price target lowered by $18 at Oppenheimer, here's why
Cautious Hold Recommendation on Inovio Pharmaceuticals Amid Financial Challenges and Competitive Pressures
Inovio price target lowered to $5 from $12 at H.C. Wainwright
Inovio price target lowered by $7 at H.C. Wainwright, here's why